EE200000605A - Adenoviiruse efektiivne puhastamine - Google Patents

Adenoviiruse efektiivne puhastamine

Info

Publication number
EE200000605A
EE200000605A EEP200000605A EEP200000605A EE200000605A EE 200000605 A EE200000605 A EE 200000605A EE P200000605 A EEP200000605 A EE P200000605A EE P200000605 A EEP200000605 A EE P200000605A EE 200000605 A EE200000605 A EE 200000605A
Authority
EE
Estonia
Prior art keywords
adenovirus
effective purification
solution
resin
chromatography resin
Prior art date
Application number
EEP200000605A
Other languages
English (en)
Inventor
E. Carrin Miguel
Menger Marilyn
Kovesdi Imre
Original Assignee
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec, Inc. filed Critical Genvec, Inc.
Publication of EE200000605A publication Critical patent/EE200000605A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/06—Quantitative determination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N2030/621—Detectors specially adapted therefor signal-to-noise ratio
    • G01N2030/625—Detectors specially adapted therefor signal-to-noise ratio by measuring reference material, e.g. carrier without sample
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Dry Shavers And Clippers (AREA)
EEP200000605A 1998-04-22 1999-04-22 Adenoviiruse efektiivne puhastamine EE200000605A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8262898P 1998-04-22 1998-04-22
PCT/US1999/008843 WO1999054441A1 (en) 1998-04-22 1999-04-22 Efficient purification of adenovirus

Publications (1)

Publication Number Publication Date
EE200000605A true EE200000605A (et) 2002-04-15

Family

ID=22172352

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000605A EE200000605A (et) 1998-04-22 1999-04-22 Adenoviiruse efektiivne puhastamine

Country Status (20)

Country Link
US (3) US6383795B1 (et)
EP (1) EP1073721B1 (et)
JP (1) JP2002512361A (et)
AT (1) ATE303434T1 (et)
AU (1) AU756889B2 (et)
BG (1) BG104928A (et)
BR (1) BR9909789A (et)
CA (1) CA2328462C (et)
DE (1) DE69927013T2 (et)
EA (1) EA200001096A1 (et)
EE (1) EE200000605A (et)
HU (1) HUP0102209A2 (et)
IL (1) IL139040A0 (et)
IS (1) IS5673A (et)
MX (1) MXPA00010338A (et)
NO (1) NO20005295L (et)
PL (1) PL343630A1 (et)
SK (1) SK15682000A3 (et)
WO (1) WO1999054441A1 (et)
ZA (1) ZA200005363B (et)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ES2278399T3 (es) * 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
GB9915413D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Propagation method
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP3547715B2 (ja) * 2001-03-06 2004-07-28 榮 新垣 ベクター精製用装置及び方法
JP2004538005A (ja) * 2001-08-08 2004-12-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア シアル酸に結合するタンパク質を有するウイルスベクターの精製法
EP1371723A1 (en) * 2002-06-12 2003-12-17 Procorde GmbH Process for preparing an adenovirus-containing preparation
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP2007523621A (ja) * 2003-06-18 2007-08-23 オニックス ファーマシューティカルズ，インコーポレイティド ウイルスを精製するための方法
ES2391975T3 (es) * 2003-07-25 2012-12-03 Genvec, Inc. Vacunas a base de vector adenovírico
CN101335320B (zh) * 2003-09-19 2012-06-06 霆激科技股份有限公司 用于制作发光器件的方法
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
GB0411081D0 (en) * 2004-05-18 2004-06-23 Glaxo Group Ltd Novel apparatus
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1815029A4 (en) * 2004-11-03 2009-06-10 Introgen Therapeutics Inc NEW PROCESS FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS
JP4626350B2 (ja) * 2005-03-22 2011-02-09 ソニー株式会社 ハイブリダイゼーション検出に適する反応部などを有する流路系、該流路系を用いるハイブリダイゼーション検出装置
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
BRPI0618441B8 (pt) * 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
EP1808697A1 (en) * 2006-01-13 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
EP2365003A1 (en) * 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
CA2794196A1 (en) 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
SG10201600912SA (en) 2011-03-04 2016-03-30 Intrexon Corp Vectors conditionally expressing protein
CN102590431B (zh) * 2012-02-10 2014-04-02 济南康众医药科技开发有限公司 一种治疗咳嗽的中药药物组合物检测方法
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
US20180193482A1 (en) 2017-01-07 2018-07-12 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
EP3927833A4 (en) 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CA3146831A1 (en) * 2019-07-12 2021-01-21 Sangamo Therapeutics, Inc. Separation and quantification of empty and full viral capsid particles
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788223A (en) * 1985-07-26 1988-11-29 Rohm And Haas Company Low-rinse, high-capacity, weakly basic acrylic ion exchange resin
US5225989A (en) * 1988-05-19 1993-07-06 Fanuc Ltd. Apparatus and method for performing simultaneous control of control axes of a machine tool
US5019270A (en) 1989-07-06 1991-05-28 Perseptive Biosystems, Inc. Perfusive chromatography
US5228989A (en) 1989-07-06 1993-07-20 Perseptive Biosystems, Inc. Perfusive chromatography
EP0620761A1 (en) * 1991-01-04 1994-10-26 Perseptive Biosystems, Inc. Sulfonamide bonded hydrophilic coatings
US5445732A (en) 1992-06-19 1995-08-29 Sepracor Inc. Passivated porous polymer supports and methods for the preparation and use of same
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
AU722196B2 (en) * 1995-08-30 2000-07-27 Genzyme Corporation Chromatographic purification of adenovirus and AAV
CA2184132C (en) * 1995-09-21 2011-03-15 Kristina J. Hennessy An adjuvanted vaccine which is substantially free of non-host albumin
EP0944717A1 (fr) * 1996-07-01 1999-09-29 Aventis Pharma S.A. Procede de production d'adenovirus recombinants
ES2278399T3 (es) * 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
CA2356373A1 (fr) 1998-12-31 2000-07-13 Aventis Pharma S.A. Methode de separation de particules virales
EP1155120B1 (fr) 1999-02-22 2006-07-05 Transgene S.A. Procede d'obtention d'une preparation virale purifiee

Also Published As

Publication number Publication date
IL139040A0 (en) 2001-11-25
EA200001096A1 (ru) 2001-04-23
PL343630A1 (en) 2001-08-27
HUP0102209A2 (hu) 2001-09-28
CA2328462A1 (en) 1999-10-28
DE69927013T2 (de) 2006-06-29
US6586226B2 (en) 2003-07-01
WO1999054441A1 (en) 1999-10-28
SK15682000A3 (sk) 2001-05-10
DE69927013D1 (de) 2005-10-06
US20030203469A1 (en) 2003-10-30
IS5673A (is) 2000-10-20
AU3662099A (en) 1999-11-08
EP1073721B1 (en) 2005-08-31
CA2328462C (en) 2010-11-09
US20020034735A1 (en) 2002-03-21
US6383795B1 (en) 2002-05-07
BR9909789A (pt) 2000-12-26
JP2002512361A (ja) 2002-04-23
WO1999054441A8 (en) 2000-02-24
ATE303434T1 (de) 2005-09-15
MXPA00010338A (es) 2005-06-17
AU756889B2 (en) 2003-01-23
BG104928A (bg) 2001-09-28
NO20005295L (no) 2000-11-30
US7141406B2 (en) 2006-11-28
NO20005295D0 (no) 2000-10-20
EP1073721A1 (en) 2001-02-07
ZA200005363B (en) 2001-09-25

Similar Documents

Publication Publication Date Title
EE200000605A (et) Adenoviiruse efektiivne puhastamine
DK0746398T3 (da) Antistofrensning
DE69417617D1 (de) Kolonne für Flüssigkeitschromatographie
PT1308455E (pt) Composicao compreendendo anticorpos anti-her2
DE3689506D1 (de) Neue Acrylsäureamide.
DE69435170D1 (de) Extrakorporeale Vorrichtungen zur Adsorption durch Affinität
DE3580057D1 (de) Heterocylische mercaptocarbonsaeureamide, -imide und -nitrile als korrosionsinhibitoren.
DE3586068D1 (de) Fluessigkeitschromatographiesaeule.
NO165570C (no) Dekoderingssystem for personsoeker.
MX9203631A (es) Proteinas succiniladas que contienen hierro.
ATE389023T1 (de) Kontrolle der schotendehiszenz
IT8448311A0 (it) Fermaglio sganciabile
KR850009561U (ko) 자전거형 새들 조립체용 고정장치
DE69432899D1 (de) Flüssige ionische Zusammensetzungen verwendende Ionenpunktquellen hoher Luminosität
DE3688808D1 (de) Fluessigmetall-ionenquelle.
DK1062244T3 (da) Forbedrede fremgangsmåder til fremstilling af faktor VIII proteiner
FI842169L (fi) Foerbaettringar vid vinschar.
DE69509390D1 (de) Flüssigmetallionenquelle
PT840746E (pt) Metodo para purificacao de proteinas
DK0724614T3 (da) Lille glasrør indeholdende en tokomponentklæber, fremgangsmåde til fremstilling heraf samt anvendelse af glasrøret.
DK242885A (da) Apparat til overtraekning af soede sager
DE69015056D1 (de) Trennung von Antikörpern gegen Metallchelate.
IT1151798B (it) Composizione resinosa termoindurente
DE3484167D1 (de) Legierung enthaltende fluessigmetall-ion-arten.
ATA139390A (de) Neue, hochreine kristallmodifikation von l-alanin(6r-(6alpha,7beta(r)))-2-(((5-methyl-20tludescher